Therapy Insight: venous-catheter-related thrombosis in cancer patients.
Central venous catheters (CVCs) have improved the management of patients with cancer substantially, by facilitating chemotherapy and supportive therapy. The use of CVCs is associated with complications such as infection and upper-limb deep vein thrombosis (UL-DVT). The incidence of clinically overt UL-DVT related to the use of CVCs ranges between 2% and 4%. In the most recent study, the incidence of CVC-related thrombosis, as screened by venography, was approximately 18% in the absence of prophylaxis. In cancer patients with CVC-related UL-DVT, the incidence of clinically overt pulmonary embolism was between 15% and 25%, and the incidence of autopsy-proven pulmonary embolism was up to 50%. Pathogenic factors for CVC-related thrombosis include vessel injury caused by the CVC insertion procedure, venous stasis because of the indwelling CVC, and hypercoagulability associated with cancer. Recent studies have not confirmed a benefit for prophylaxis with antithrombotic agents for CVC-related thrombosis. The recommended treatment for CVC-related thrombosis is based on long-term anticoagulant therapy, with or without catheter removal.
Agnelli
Giancarlo
G
Internal Medicine, University of Perugia, Italy. agnellig@unipg.it
Verso
Melina
M
D002405:Catheterization, Central Venous / Q000009:adverse effects*; D006801:Humans; D009369:Neoplasms / Q000097:blood / Q000628:therapy*; D020246:Venous Thrombosis / Q000209:etiology* / Q000628:therapy